← All trials
NCT04335669
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 20, 2019
- Primary completion
- Jun 25, 2023
- Completion date
- Dec 25, 2032
- First posted
- Apr 6, 2020
- Last posted
- Apr 6, 2020
- Enrollment
- 820
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Lund UniversityLead sponsor
- Lund UniversityStudy director
- Danish Breast Cancer Cooperative GroupCollaborator
- Swedish Breast Cancer GroupCollaborator
- Finnish Breast Cancer GroupCollaborator
- Icelandic Breast Cancer GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.